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Abstract
Background: Increasing evidence shows that Human Papillomavirus (HPV) is preferentially associated with some
head and neck squamous cell carcinomas (HNSCCs), with variable infection rates reported.
Methods: We assessed HPV involvement in HNSCC using the Roche Linear Array HPV Genotyping Test, which can
detect 37 different HPV types. We examined the prevalence of HPV infection in 92 HNSCCs (oropharynx, oral cavity,
and other HNSCC sites).
Results: HPV was frequently detected in oropharyngeal cancers (OPCs) (16/22, 73%), but was uncommon in oral
cavity cancers (2/53, 4%), and in other HNSCC subsites (1/17, 6%). HPV positive tumors were associated with
patients that were 40-60 years old (p = 0.02), and node positive (p = < 0.0001). HPV 16 was the most prevalent
type, but other types detected included 6, 18, 33, 35, 45, and 52/58.
Conclusion: Our results show that in contrast to oropharyngeal cancers, oral cancers and other HNSCCs
infrequently harbor HPV.
Introduction
In 2009, head and neck squamous cell carcinoma
(HNSCC) had an estimated incidence of 48,010 cases
(11,260 deaths) within the U.S. (American Cancer
Society), and 4,550 cases (1,660 deaths) in Canada
(Canadian Cancer Society). The most common risk fac-
tors for HNSCC development are excessive tobacco
and/or alcohol consumption [1]. In addition, human
papillomavirus (HPV) infection has been associated with
some HNSCC subsites [2].
Most HPV research has primarily focused on cervical
cancer, as >99% of cervical cancers harbor HPV [3].
Over 130 HPV types are known; these are classified as
low- or high-risk based on their association with cervical
carcinoma. HPV-16 and HPV-18 are the most com-
monly detected high-risk types [3]. High-risk HPVs pro-
mote tumorigenesis through expression of the E6 and
E7 oncoproteins, which inactivate the tumor suppressors
TP53 and RB1, respectively [4]. HPV-positive tumors
often show CDKN2A/P16 over-expression due to a
feedback mechanism involving RB1 inactivation [5].
D a t af r o mt h el i t e r a t u r es h o ww i d e l yv a r i a b l eH P V
infection rates in HNSCC [6-10]. This variability may be
attributable to: sample storage and preparation of DNA
[11]; ethnicity and geography [10,12]; small number of
samples analyzed [10]; possible contamination [7]; detec-
tion technique used, and HNSCC site analyzed [6,7]. In
a case-controlled study of HPV infection in HNSCC,
HPV-16 was present in 72% of oropharyngeal carcino-
mas (OPCs), and associated with specific sexual beha-
viors [13], and marijuana use [14]. Unlike the striking
association with oropharyngeal cancers, the incidence of
HPV in other head and neck sites remains unclear.
Interestingly, HPV positive HNSCCs are biologically dif-
ferent than HPV negative tumors, as shown by distinct
gene expression profiles [15,16]. Importantly, patients
with HPV positive HNSCC have better survival due to
increased sensitivity to chemoradiotherapy [11].
We examined the prevalence of HPV in oral squa-
mous cell carcinomas (OSCCs), compared to other head
and neck subsites and OPCs. For HPV detection and
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the Roche Linear Array HPV Genotyping test was used
for these studies.
Materials and methods
Patients
The University Health Network (UHN) Research Ethics
Board approved this study; informed consent was
obtained from all patients prior to sample collection.
Medical records were examined to obtain detailed clini-
cal and histopathological information, including age, sex,
disease site, histopathological diagnosis, disease stage,
history of tobacco and alcohol use, nodal metastasis,
treatment, and outcome. Subsets of patients were classi-
fied as social or rare alcohol drinkers as written in their
clinical reports. Patients having no use of tobacco or
alcohol within one year prior to surgery were classified
as former smokers and drinkers, respectively. Tumors
were staged according to the current TNM classifica-
tion, as recommended by the American Joint Committee
on Cancer (UICC, 2002).
Patients over 60 years of age often present with
HNSCC, whereas young patients with HNSCC are often
characterized as patients under 35-45 years of age [17].
T h ep a t i e n t se x a m i n e di no u rs t u d yw e r es t r a t i f i e da s
young (≤ 40 years of age), intermediate age (>40 and
<60) or older patients (≥ 60 years old). The median age
was 59 (range, 22-93 years of age). The male-female
ratio was approximately 2:1. Median follow up time was
22 months (range, 1-140 months).
Tumor samples and DNA isolation
The 92 samples used in this study were retrospectively
collected between 1995-2007. 78 HNSCC samples were
o b t a i n e da tt h et i m eo fs u r g e r yf r o mt h eT o r o n t oG e n -
eral Hospital. Tissues were snap frozen and stored in
liquid nitrogen. Also, 14 HNSCC were formalin fixed
paraffin embedded samples. H&E stained sections were
examined by histopathology (B.P-O.) to confirm >80%
tumor in the specimens being tested.
DNA was isolated following fresh frozen tissue homo-
genization in liquid nitrogen using a cold steel mortar
and pestle. Homogenized tissue was lysed in SNET buf-
fer (1% SDS, 400 mM NaCl, 5 mM EDTA, 20 mM Tris,
pH 8.0), containing 400 μg/mL proteinase K overnight
at 55°C. After digestion, 25 mg/mL RNase was added
and DNA was extracted by standard techniques using
phenol/chloroform and ethanol precipitation. DNA
quantity and quality was assessed by spectrophotometry
(Nanodrop, Thermo Scientific, Waltham, MA) and elec-
trophoresis on a 0.8% agarose gel. Genomic DNA was
isolated from formalin fixed paraffin embedded (FFPE)
samples using the DNeasy Blood and Tissue Kit (Qia-
gen, Valencia, CA).
HPV detection
The Roche Linear Array HPV Genotyping test (Roche
Diagnostics, Branchburg, NJ) was used for the detection
of 37 low- and high-risk HPV types, according to manu-
facturer’s instructions. Briefly, it utilizes biotinylated
PCR of the HPV L1 region and reverse blotting to mul-
tiple HPV genotypes. HPV types were determined by
lining up the manufacturer’s HPV reference guide with
the genotyping strip. A low- and high-copy b-globin
internal control is included in each run to assess the
quality of DNA sample. All experiments included an
HPV positive control, an HPV negative control, and a
no-template control. Cases that were HPV positive were
repeated, without the presence of a positive control, to
verify results and exclude the risk of contamination.
Statistical methods
Descriptive statistics were examined as median and
range for continuous variables, and frequencies and pro-
portions for categorical variables. The Fisher’s exact and
Pearson’s chi-square tests were used for statistical eva-
luation. Overall survival was calculated using the
Kaplan-Meier method. A Cox Proportional Hazard
regression model was applied for continuous predictors.
Results were considered significant if p ≤ 0.05. Statistical
analyses were performed using the SAS 9.1 software
package (SAS Institute, Cary, NC).
Results
All 92 HNSCC samples had a positive b-globin internal
control on the linear array and were thus suitable for
HPV analysis. Of these, 53 were from sites in the oral
cavity: tongue, floor of mouth (FOM), palate, buccal
mucosa and gingiva; 17 were from other sites (pharynx,
nasopharynx, hypopharynx and larynx); and 22 were
from the oropharynx (base of tongue and tonsil). The
oropharyngeal cases were selected for comparison, as
these tumors have a higher incidence of HPV infection.
HPV positivity was stratified according to distinct
HNSCC subsites: 2/53 (4%) OSCCs, 16/22 (73%) OPCs,
a n d1 / 1 7( 6 % )t u m o r sf r o mo t h e rH N S C Cs i t e sw e r e
HPV positive. HPV positivity was significantly associated
with OPCs (p < 0.0001) (Table 1). The most prevalent
HPV subtype found in our analysis was the high-risk
HPV-16 (12/19 cases) (Figure 1), which is the most com-
mon subtype observed in HNSCC [10]. We detected low-
risk HPV-6 in one sample, and high-risk HPV types: 18,
33, 35, 45, and 52/58. 3/19 HPV positive cases, which
were OPCs had confirmed multiple infections; and 1/19
HPV positive cases (Tongue SCC) had a low-level infec-
tion of HPV-18, as compared to the b-globin control.
HPV was significantly associated in node positive
patients vs. node negative patients (p < 0.0001) (Table
1). When we stratified individuals into young (≤ 40
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older (≥ 60 years old) HNSCC patients, HPV positive
tumors were associated with the intermediate age
patient group (p = 0.02). There were no significant asso-
ciations between HPV and smoking or alcohol status.
We also found no association between HPV infection
and tumor differentiation and stage. In other studies,
these associations have been inconsistent [6].
Survival was not significantly different for HPV-posi-
tive vs. HPV-negative HNSCCs (p = 0.24) (Table 1), as
non-OPC sites were mainly HPV negative. Further
examination of the 22 patients with OPC showed that
outcomes for patients with HPV positive tumors
included: 1/16 patients was alive with disease, 14/16
patients were alive with no evidence of disease, and 1/16
had lost to follow up. In contrast, 3/6 patients with HPV
Table 1 Statistical association of clinical factors and HPV status
Category Variable Patients (#) HPV + (%) p-value
Age < = 40 22 1 (4.5) 0.02
>40 and <60 28 10 (35.7)
> = 60 42 8 (19)
Sex F 28 4 (14.3) 0.32
M 64 15 (23.4)
Smoking Y 53 11 (20.8) 0.59
N 32 6 (18.8)
Former 5 0 (0)
Alcohol Y 46 9 (19.6) 0.47
N 19 2 (10.5)
Former 6 0 (0)
Other 18 5 (27.8)
Stage I 6 0 (0) 0.12
II 22 1 (4.5)
III 21 5 (23.8)
IV 40 10 (25)
Tumor Differentiation Well 1 0 (0) 0.51
Moderately 68 12 (17.6)
Poorly 18 5 (27.8)
Other 5 2 (40)
Site Tongue 29 1 (3.4) < 0.0001
FOM 8 1 (12.5)
FOM+Tongue 6 0 (0)
Oropharynx (Base of Tongue) 22 16 (72.7)
Larynx/Pharynx/Nasopharynx 17 1 (5.9)
Other 10 0 (0)
Node + 43 15 (34.9) < 0.0001
- 46 1 (2.2)
Outcome Alive 83 17 (20.5) 0.24
Dead 7 0 (0)
HPV +1 9
-7 3
Clinical categories and the variables were examined for significant associations with HPV status. Statistical significance was assessed by Fisher’s exact and
Pearson’s chi-square tests (p ≤ 0.05). M - Male; F – Female; Y – Yes; N – No; FOM – Floor of Mouth. Unknown values were not included in analysis.
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were alive with no evidence of disease and 1/6 patients
died of disease. Regardless of HPV status, we observed a
significant gender-based difference in overall survival. Of
the 7 deceased patients, 5 were females, non-smokers
and non-drinkers; 3 of these were young and 2 were
older patients; all of these patients were HPV negative.
It has been suggested that a subgroup of young non-
smoking female patients may have an aggressive form of
HNSCC [18], although this would have to be tested in a
larger cohort of patients.
Discussion
In our study, we sought to determine HPV infection
rates in OSCC, in comparison to other HNSCC sites
such as OPC. We observed significant differences in
HPV positivity among different HNSCC sites, with
OPCs having the highest infection rate. We also
detected a low infection rate within OSCC samples. In
the literature, most HPV studies do not provide stratifi-
cation between oral cavity subsites, e.g. mobile tongue
vs. base of tongue; the latter is associated with a higher
HPV prevalence due to the involvement of the orophar-
ynx [11]. Indeed, high HPV prevalence has been consis-
tently shown in OPC compared to a lower prevalence in
other HNSCCs [19]. A recent comprehensive examina-
tion of the Surveillance, Epidemiology and End Results
(SEER) database showed a significant increase in HPV-
related vs. HPV-unrelated OPCs from 1973-2004 [20].
In this SEER analysis, HPV-related HNSCCs mainly
involved the oropharynx (base of tongue, and palatine
tonsils), whereas HPV-unrelated HNSCCs were from
the mobile tongue, floor of mouth and palate. Gillison
et al. used in situ hybridization for HPV detection and
showed a higher frequency of HPV in tumors of the
oropharynx, low frequency in larynx and oral cavity, and
an absence of HPV in the hypopharynx or nasopharynx
[14].
In our study, we observed a significant association of
HPV positive tumors to be present in HNSCCs from
intermediate age patients. It has been suggested that,
f r o mt h et i m eo fs e x u a lt r a n s m i s s i o no fH P V ,ac l i n i c a l
lesion can appear within two decades, in contrast to
conventional risk factors (tobacco smoking and alcohol
consumption), which may take several decades [21].
Interestingly, HPV positive HNSCCS have also been
associated with lymph node metastasis. For example, in
another study, HPV positive salivary samples were cor-
related with node-positive patients, suggesting that HPV
infection may result from a cellular immunological defi-
ciency that impedes the cancer cell’s ability to clear
HPV and thus result in cancer development, recurrence
and metastasis [22]. Among patients with lymph node
metastasis, HPV positive patients have a better prog-
nosis than HPV negative patients, due to a better
response to radiotherapy [23]. We did not detect signifi-
cant differences in survival for patients with HPV posi-
tive vs. negative tumors, as most OSCCs were HPV
negative in our study, and possibly due to the relative
small sample size of OPCs analyzed.
Some studies have shown a higher prevalence of HPV
in OSCCs and other head and neck sites outside the
oropharynx. For example, examination of HPV status in
OSCC from 50 Brazilian patients (excluding OPC),
showed 24% HPV positivity, mostly HPV-16/18 [24]. In
a Mexican patient cohort, a high frequency of HPV
positivity (43.5%) was found in OSCC [25]. Such differ-
ences may be attributable to different HPV susceptibil-
ities in different ethnicities/geographic regions or they
may be due to different HPV detection methods. Boy et
al. detected 7/59 (12%) HPV-18 positivity in oral cancer
using quantitative real-time PCR and 0% positivity when
using in situ hybridization assays on the same samples
[26]. Our data have added to the literature by using a
sensitive and comprehensive HPV detection and geno-
typing assay in HNSCC. This assay is currently used as
Figure 1 Head and neck cancer sites and detected HPV types. HPV types were highly associated with the oropharynx and rarely detected in
oral cavity cancers and other head and neck cancer sites.
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genotyping in cervical carcinomas in Europe [27]. In our
study, by using this robust HPV detection and genotyp-
ing method, we showed that HPV is rarely involved in
oral carcinomas and other non-OPC head and neck
sites.
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